Gene construct encoding mutant Thioesterase, mutant Thioesterase encoded thereby, transformed host cell containing the gene construct, and method of using them to produce medium-chain fatty acids
Unnatural, mutated thioesterases having an amino acid sequence that is at least 80% identical to SEQ. ID. NO: 1 and having substitutions at one or more of amino acid positions I107, R108, L109, S122, M141, E142, Y145, and L146, gene constructs encoding and configured to express the mutated thioesterases in a transformed host cell and host cells transformed to contain the gene constructs.
1. An unnatural, mutated protein comprising an amino acid sequence that is at least 85% identical to SEQ ID NO:1 and comprises one or more substitutions with respect to SEQ ID NO:1, wherein the protein has at least one of enhanced thioesterase activity and enhanced thioesterase specificity in catalyzing the hydrolysis of a medium-chain acyl-acyl carrier protein substrate or a medium-chain acyl-CoA substrate to yield a free fatty acid or a free fatty acid derivative compared to an unaltered protein of SEQ ID NO:1, wherein the one or more substitutions comprise one or more of:
a lysine at a position aligning to R108 of SEQ ID NO:1;
a tyrosine at a position aligning to F139 of SEQ ID NO:1;
a valine at a position aligning to 142 of SEQ ID NO:1;
a glycine at a position aligning to A111 of SEQ ID NO:1;
a serine at a position aligning to P138 of SEQ ID NO:1;
an isoleucine at a position aligning to M170 of SEQ ID NO:1;
a serine at a position aligning to T35 of SEQ ID NO:1; and
an aspartate as a position aligning to E142 of SEQ ID NO:1.
2. The protein of claim 1 , wherein the one or more substitutions comprise the lysine at the position aligning to R108 of SEQ ID NO:1.
3. The protein of claim 1 , wherein the one or more substitutions comprise the tyrosine at the position aligning to F139 of SEQ ID NO:1.
4. The protein of claim 3 , wherein the one or more substitutions further comprise:
a phenylalanine at a position aligning to V38 of SEQ ID NO:1; and
a cysteine at a position aligning to Y145 of SEQ ID NO:1.
5. The protein of claim 1 , wherein the one or more substitutions comprise one or more of:
the valine at the position aligning to 142 of SEQ ID NO:1;
the glycine at the position aligning to A111 of SEQ ID NO:1; and
the serine at the position aligning to P138 of SEQ ID NO:1.
6. The protein of claim 1 , wherein the one or more substitutions comprise:
the valine at the position aligning to 142 of SEQ ID NO:1;
the glycine at the position aligning to A111 of SEQ ID NO:1; and
the serine at the position aligning to P138 of SEQ ID NO:1.
7. The protein of claim 6 , wherein the one or more substitutions further comprise:
an alanine at a position aligning to G75 of SEQ ID NO:1; and
an arginine at a position aligning to Q106 of SEQ ID NO:1.
8. A gene construct encoding the protein of claim 1 .
9. The gene construct of claim 8 , comprising a nucleotide regulatory sequence operationally connected to nucleotides encoding the protein, wherein the regulatory sequence is dimensioned and configured to drive expression of the protein in a host cell transformed to contain the gene construct.
10. A host cell transformed to contain and express a gene construct encoding the protein of claim 1 .
11. The host cell of claim 10 , which is selected from the group consisting of a transformed microbe, a transformed eukaryote, a transformed prokaryote, and a transformed plant cell.
12. The protein of claim 1 , wherein the one or more substitutions comprise the isoleucine at the position aligning to M170 of SEQ ID NO:1.
13. The protein of claim 12 , wherein the one or more substitutions further comprise a proline at the position aligning to S47 of SEQ ID NO:1.
14. The protein of claim 1 , wherein the one or more substitutions comprise one or more of:
the serine at the position aligning to T35 of SEQ ID NO:1; and
the aspartate at the position aligning to E142 of SEQ ID NO:1.
15. The protein of claim 1 , wherein the one or more substitutions comprise:
the serine at the position aligning to T35 of SEQ ID NO:1; and
the aspartate at the position aligning to E142 of SEQ ID NO:1.